Publications by authors named "K Arvanitakis"
Background: Gut microbiota-derived metabolite Trimethylamine-N-oxide (TMAO) is increasingly recognized as a potential novel prognostic biomarker for cardiovascular disease. Our research work aimed to investigate the potential utility of TMAO measurement in patients with STelevation Myocardial Infarction (STEMI).
Methods: We performed a systematic literature search in PubMed from inception to the 1st of February 2024 to identify all studies examining the association between plasma TMAO levels and disease complexity or clinical outcomes in STEMI patients.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common chronic liver disorder in Western countries, encompassing a range of conditions from steatosis to Metabolic Dysfunction-Associated Steatohepatitis (MASH), which can potentially progress to cirrhosis. Lipidomics approaches have revealed significant alterations in the hepatic lipidome associated with both steatosis and steatohepatitis, with these changes correlating with disease manifestation. While the transition from steatosis to MASH remains poorly understood, recent research indicates that both the quantity and quality of deposited lipids play a pivotal role in MASLD progression.
View Article and Find Full Text PDFMetabolic dysfunction-associated steatotic liver disease (MASLD) and polycystic ovary syndrome (PCOS) are prevalent conditions that have been correlated with infertility through overlapped pathophysiological mechanisms. MASLD is associated with metabolic syndrome and is considered among the major causes of chronic liver disease, while PCOS, which is characterized by ovulatory dysfunction and hyperandrogenism, is one of the leading causes of female infertility. The pathophysiological links between PCOS and MASLD have not yet been fully elucidated, with insulin resistance, hyperandrogenemia, obesity, and dyslipidemia being among the key pathways that contribute to liver lipid accumulation, inflammation, and fibrosis, aggravating liver dysfunction.
View Article and Find Full Text PDFArticle Synopsis
- Hepatocellular carcinoma (HCC) is the leading type of primary liver cancer, with increasing incidence and high mortality rates, and there are currently limited curative treatment options available despite advances in diagnosis and therapy.
- Recent advances in understanding the tumor microenvironment have brought attention to immunotherapy as a promising approach for treating advanced HCC, although only a small number of patients benefit from existing solutions.
- The glucocorticoid-induced TNFR-related protein (GITR) shows potential as a therapeutic target for HCC due to its role in enhancing T-cell function and inhibiting regulatory T-cells, along with evidence suggesting it may aid in anti-tumor effects and liver regeneration.
Editorial: GLP-1 receptor agonists in inflammatory bowel disease-Is it time?
Aliment Pharmacol Ther
September 2024